Duobrii in Combination With Biologics
Purpose
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Condition
- Psoriasis
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures
Exclusion Criteria
- Psoriasis affecting ˂2% or >10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent <24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Intervention Model Description
- open label
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Open Label Duobrii |
Duobrii QD |
|
Recruiting Locations
Psoriasis Treatment Center of Central New Jersey
East Windsor 8354649, New Jersey 5101760 08520
East Windsor 8354649, New Jersey 5101760 08520
More Details
- Status
- Recruiting
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Detailed Description
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks